Literature DB >> 23376112

The role of proton dynamics in the development and maintenance of multidrug resistance in cancer.

Chloë Daniel1, Charlotte Bell, Christopher Burton, Salvador Harguindey, Stephan J Reshkin, Cyril Rauch.   

Abstract

With a projected 382.4 per 100,000 people expected to suffer from some form of malignant neoplasm in 2015, improving treatment is an essential focus of cancer research today. Multi-drug resistance (MDR) is the leading cause of chemotherapeutic failure in the treatment of cancer, the term denoting a characteristic of the disease-causing agent to avoid damage by drugs designed to bring about their destruction. MDR is also characterised by a reversal of the pH gradient across cell membranes leading to an acidification of the outer milieu and an alkalinisation of the cytosol that is maintained by the proton pump vacuolar-type ATPase (V-ATPase) and the proton transporters: Na(+)/H(+) exchanger (NHE1), Monocarboxylate Transporters (MCTs), Carbonic anhydrases (CAs) (mainly CA-IX), adenosinetriphosphate synthase, Na(+)/HCO3(-) co-transporter and the Cl(-)/HCO3(-)exchanger. This review aims to give an introduction to MDR. It will begin with an explanation for what MDR actually is and go on to look at the proposed mechanisms by which a state of drug resistance is achieved. The role of proton-pumps in creating an acidic extracellular pH and alkaline cytosol, as well as key biomechanical processes within the cell membrane itself, will be used to explain how drug resistance can be sustained.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23376112     DOI: 10.1016/j.bbadis.2013.01.020

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  42 in total

Review 1.  The key role of extracellular vesicles in the metastatic process.

Authors:  Hongyun Zhao; Abhinav Achreja; Elisabetta Iessi; Mariantonia Logozzi; Davide Mizzoni; Rossella Di Raimo; Deepak Nagrath; Stefano Fais
Journal:  Biochim Biophys Acta Rev Cancer       Date:  2017-11-24       Impact factor: 10.680

Review 2.  The acidic microenvironment as a possible niche of dormant tumor cells.

Authors:  Silvia Peppicelli; Elena Andreucci; Jessica Ruzzolini; Anna Laurenzana; Francesca Margheri; Gabriella Fibbi; Mario Del Rosso; Francesca Bianchini; Lido Calorini
Journal:  Cell Mol Life Sci       Date:  2017-03-22       Impact factor: 9.261

3.  Selective inhibition of tumor cell associated Vacuolar-ATPase 'a2' isoform overcomes cisplatin resistance in ovarian cancer cells.

Authors:  Arpita Kulshrestha; Gajendra K Katara; Jordyn Ginter; Sahithi Pamarthy; Safaa A Ibrahim; Mukesh K Jaiswal; Corina Sandulescu; Ramayee Periakaruppan; James Dolan; Alice Gilman-Sachs; Kenneth D Beaman
Journal:  Mol Oncol       Date:  2016-01-29       Impact factor: 6.603

Review 4.  Cancer cell behaviors mediated by dysregulated pH dynamics at a glance.

Authors:  Katharine A White; Bree K Grillo-Hill; Diane L Barber
Journal:  J Cell Sci       Date:  2017-02-15       Impact factor: 5.285

5.  TM9SF4 is a novel V-ATPase-interacting protein that modulates tumor pH alterations associated with drug resistance and invasiveness of colon cancer cells.

Authors:  F Lozupone; M Borghi; F Marzoli; T Azzarito; P Matarrese; E Iessi; G Venturi; S Meschini; A Canitano; R Bona; A Cara; S Fais
Journal:  Oncogene       Date:  2015-02-09       Impact factor: 9.867

6.  Proteomic identification of a marker signature for MAPKi resistance in melanoma.

Authors:  Verena Paulitschke; Ossia Eichhoff; Christopher Gerner; Philipp Paulitschke; Andrea Bileck; Thomas Mohr; Phil F Cheng; Alexander Leitner; Emmanuella Guenova; Ieva Saulite; Sandra N Freiberger; Anja Irmisch; Bernhard Knapp; Nina Zila; Theodora-Pagona Chatziisaak; Jürgen Stephan; Joanna Mangana; Rainer Kunstfeld; Hubert Pehamberger; Ruedi Aebersold; Reinhard Dummer; Mitchell P Levesque
Journal:  EMBO J       Date:  2019-06-26       Impact factor: 11.598

7.  Cancer cell bioenergetics and pH regulation influence breast cancer cell resistance to paclitaxel and doxorubicin.

Authors:  Diana Tavares-Valente; Fátima Baltazar; Roxana Moreira; Odília Queirós
Journal:  J Bioenerg Biomembr       Date:  2013-06-30       Impact factor: 2.945

8.  Understanding Drug Resistance in Breast Cancer with Mathematical Oncology.

Authors:  Terisse Brocato; Prashant Dogra; Eugene J Koay; Armin Day; Yao-Li Chuang; Zhihui Wang; Vittorio Cristini
Journal:  Curr Breast Cancer Rep       Date:  2014-06-01

Review 9.  Hurdles in selection process of nanodelivery systems for multidrug-resistant cancer.

Authors:  P S Thakur; A M Khan; S Talegaonkar; F J Ahmad; Z Iqbal
Journal:  J Cancer Res Clin Oncol       Date:  2016-04-26       Impact factor: 4.553

10.  Spearhead Nanometric Field-Effect Transistor Sensors for Single-Cell Analysis.

Authors:  Yanjun Zhang; Jan Clausmeyer; Babak Babakinejad; Ainara López Córdoba; Tayyibah Ali; Andrew Shevchuk; Yasufumi Takahashi; Pavel Novak; Christopher Edwards; Max Lab; Sahana Gopal; Ciro Chiappini; Uma Anand; Luca Magnani; R Charles Coombes; Julia Gorelik; Tomokazu Matsue; Wolfgang Schuhmann; David Klenerman; Elena V Sviderskaya; Yuri Korchev
Journal:  ACS Nano       Date:  2016-02-01       Impact factor: 15.881

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.